Palvella Therapeutics, Inc. PVLA

Palvella Therapeutics completes rolling submission of New Drug Application to FDA for QTORIN rapamycin to treat microcystic lymphatic malformations. NDA submission completion advances potential approval and commercialization of lead candidate.

Palvella Therapeutics targets 2027 QTORIN approval while expanding its rare-disease pipeline. Targeted 2027 approval and rare disease pipeline growth position Palvella for substantial future advancement.

Palvella Therapeutics, Inc. (PVLA) held its Q2 2026 earnings call covering financial results, business updates and outlook. Quarterly earnings calls disclose financial metrics and forward guidance that can shift near-term investor sentiment and valuation.

Palvella Therapeutics (PVLA) valuation faces scrutiny ahead of QTORIN approval decision. QTORIN approval is a major regulatory event that can significantly shift company trajectory and investor sentiment.

Palvella Therapeutics Inc reported strong Phase 3 data during its Q2 2026 earnings call. Strong Phase 3 data signals major regulatory and commercial upside for Palvella's lead program.

Palvella Therapeutics, Inc. held its Q2 2026 earnings call. Earnings call updates financial results and outlook for Palvella Therapeutics.

Palvella Therapeutics held Q2 earnings call covering financial results, operational updates, and outlook. Q2 earnings call delivers financial metrics and guidance with moderate effect on near-term valuation.

Palvella Therapeutics (PVLA) submitted the initial module of its NDA for QTORIN. NDA submission represents major regulatory milestone advancing QTORIN toward potential approval.

Palvella Therapeutics submitted the first module of its rolling New Drug Application to the FDA for QTORIN rapamycin to treat microcystic lymphatic malformations. NDA module submission advances regulatory path for lead drug candidate and may drive significant valuation gains.

Palvella Therapeutics (PVLA) shares advance after FDA grants rolling review for its rare disease therapy. FDA rolling review accelerates potential approval path for core rare disease therapy.

FDA grants rolling review of Palvella Therapeutics' QTORIN rapamycin NDA for microcystic lymphatic malformations. FDA rolling NDA review accelerates potential approval of lead drug candidate and lifts company prospects.

Palvella Therapeutics completed FDA Pre-NDA meeting for QTORIN rapamycin in microcystic lymphatic malformations. Completion of Pre-NDA meeting advances QTORIN rapamycin toward potential FDA approval and commercialization.

Palvella Therapeutics licensed a U.S. patent from Yale for QTORIN™ Pitavastatin, extending intellectual property protection through 2043. Yale-licensed patent extends QTORIN Pitavastatin exclusivity to 2043 and bolsters long-term competitive positioning.

Palvella Therapeutics presented new SELVA and TOIVA data at the 2026 ISSVA World Congress supporting QTORIN Rapamycin as a potential first-in-disease therapy for multiple serious rare vascular malformations. Positive clinical data on QTORIN Rapamycin for rare vascular malformations boosts prospects for first-in-disease approval and elevates company trajectory.

Palvella Therapeutics released positive QTORIN trial data that improves venous malformation treatment prospects and raises company valuation. Positive QTORIN trial results for venous malformations represent major clinical progress that can significantly shift Palvella's trajectory and investor sentiment.

Palvella Therapeutics announced new data from the Phase 2 TOIVA trial of QTORIN™ rapamycin in cutaneous venous malformations, presented at the 83rd Annual Meeting of the Society for Investigative Dermatology. Positive Phase 2 data presentation for QTORIN™ in a rare disease strengthens PVLA's clinical pipeline and investor sentiment.

Palvella Therapeutics, Inc. (PVLA) announces uplisting to the Nasdaq Global Market from Nasdaq Capital Market, effective upon SEC approval of Form 8-A and meeting initial listing requirements. Uplisting to Nasdaq Global Market boosts stock liquidity, visibility, institutional investor access, and market credibility.

Palvella Therapeutics released Q1 earnings call highlights covering financial results, pipeline progress, and business updates. Q1 earnings highlights impact financial performance and investor sentiment on pipeline advancements.

Palvella Therapeutics reported first quarter 2026 financial results and provided a corporate update. Q1 financial results and corporate update highlight pipeline progress and cash position, significantly influencing investor sentiment and stock trajectory.

Palvella Therapeutics doses first patients in Phase 2 LOTU trial of Fast Track-designated QTORIN™ rapamycin for clinically significant angiokeratomas. Initiating Phase 2 dosing for a Fast Track-designated therapy marks a key clinical milestone that could significantly enhance Palvella's pipeline value and market perception.

Palvella Therapeutics to present QTORIN™ Rapamycin results from Phase 3 SELVA and Phase 2 TOIVA studies at the International Society for the Study of Vascular Anomalies World Congress 2026. Presentation of Phase 3 SELVA results signals potential regulatory progress and could drive significant investor sentiment and stock performance.

Palvella Therapeutics appoints Kent Taylor, an accomplished commercial leader, as Senior Vice President of Sales. Appointing an experienced sales executive signals strengthened commercialization readiness, potentially boosting revenue trajectory and investor confidence.

Palvella Therapeutics achieves Phase III trial success and FDA Fast Track status, challenging its current valuation amid potential for accelerated approval. Phase III success and Fast Track status enable rapid regulatory approval, fundamentally redefining Palvella's competitive position and long-term prospects.

Palvella Therapeutics Inc (PVLA) highlighted strategic advances in Q4 2025 earnings call, covering key operational updates and future outlook. Strategic advances in Q4 2025 earnings call indicate major moves that could significantly boost PVLA's competitive position and investor sentiment.

Palvella Therapeutics released Q4 earnings call highlights covering financial results, pipeline updates, and strategic outlook. Q4 earnings highlights detail financial performance, clinical progress, and future plans significantly shaping investor sentiment and stock trajectory.

Palvella Therapeutics reported full year 2025 financial results and provided a corporate update. Full-year financial results and corporate update significantly influence investor sentiment, cash position, and pipeline progress for PVLA.

Palvella Therapeutics highlights continued progress across its rare skin disease pipeline with two poster presentations at the 2026 American Academy of Dermatology Annual Meeting. Poster presentations on pipeline progress offer moderate visibility into rare skin disease programs, potentially influencing investor sentiment without fundamentally altering trajectory.

Palvella Therapeutics director buys $500,000 in company shares following successful Phase 3 trial results. Phase 3 success positions Palvella for potential drug approval and commercialization, amplified by director's confident insider purchase signaling strong future prospects.

Palvella Therapeutics appoints Jennifer J. McDonough, a seasoned rare disease commercial leader, as Senior Vice President of Market Access and Patient Services to strengthen its leadership team. Appointment of experienced rare disease commercial leader bolsters commercialization strategy and market positioning without fundamentally transforming operations.

Palvella Therapeutics announces issuance of a European patent covering anhydrous compositions of rapamycin. European patent issuance strengthens Palvella Therapeutics' IP protection for key rapamycin formulations, enhancing competitive moat and commercialization prospects.